Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection.

ABSTRACT: Oncology has seen growing use of newly developed targeted therapies. Although this has resulted in dramatic improvements in progression-free and overall survival, challenges in the management of toxicities related to longer-term treatment of these therapies have also become evident. Although a targeted approach often exploits the differences between cancer cells and noncancer cells, overlap in signaling pathways necessary for the maintenance of function and survival in multiple cell types has resulted in systemic toxicities. In particular, cardiovascular toxicities are of important concern. In this review, we highlight several targeted therapies commonly used across a variety of cancer types, including HER2 (human epidermal growth factor receptor 2)+ targeted therapies, tyrosine kinase inh

SUBMITTER: Hahn VS 

PROVIDER: S-EPMC8765442 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature